Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001349525 | SCV001543876 | uncertain significance | not provided | 2020-10-19 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed in individual(s) with atypical hemolytic uremic syndrome (PMID: 28939980). This variant is present in population databases (rs766710327, ExAC 0.01%). This sequence change replaces proline with leucine at codon 40 of the THBD protein (p.Pro40Leu). The proline residue is weakly conserved and there is a moderate physicochemical difference between proline and leucine. |
Fulgent Genetics, |
RCV002486436 | SCV002798300 | uncertain significance | Atypical hemolytic-uremic syndrome with thrombomodulin anomaly; Thrombomodulin-related bleeding disorder | 2022-01-18 | criteria provided, single submitter | clinical testing |